Pilot Study on the Feasibility, Safety and Immunogenicity of a Personalized Neoantigen-Targeted Immunotherapy (NeoPepVac) in Combination with Anti-PD-1 or Anti-PD-L1 in Advanced Solid Tumors

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 30; p. xi41
Main Authors Moerk, S.K., Donia, M., Kringelum, J.V., Bogenrieder, T., Rønø, B., Sorensen, A.B., Draghi, A., Bol, K.F., Petersen, N.V., Kadivar, M., Hernandez, S.S., Hadrup, S. Reker, Andreasen, L.V., Christensen, D., Andersen, P.L., Svane, I.M.
Format Journal Article
LanguageEnglish
Published 01.12.2019
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1093/annonc/mdz451.019